The CCDC85C antibody is a valuable tool for studying the coiled-coil domain-containing protein 85C (CCDC85C), also known as DIPA. This protein is a nuclear envelope-associated scaffold protein implicated in various cellular processes, including cell polarity, cytoskeletal organization, and transcriptional regulation. CCDC85C interacts with proteins like β-catenin and emerin, playing roles in Wnt/β-catenin signaling and nuclear membrane integrity. Its dysfunction has been linked to neurodevelopmental disorders, cancer progression, and muscular dystrophy.
CCDC85C antibodies are widely used in techniques such as Western blotting, immunofluorescence, and immunohistochemistry to detect endogenous CCDC85C expression, localization, and interactions in cells or tissues. Researchers employ these antibodies to explore CCDC85C's role in diseases—for instance, its altered expression in breast cancer or glioblastoma, or its involvement in neuronal migration defects. Commercial CCDC85C antibodies are typically validated for specificity using knockout controls or siRNA-mediated knockdown.
Despite its utility, challenges remain in standardizing antibody performance across experimental conditions. Ongoing studies aim to clarify CCDC85C's precise molecular mechanisms and therapeutic potential. The antibody thus serves as a critical reagent for dissecting CCDC85C's multifaceted contributions to cellular homeostasis and pathology.